# PKM2 & the Warburg Effect The PKM2 story is the centre of the shikonin literature. It is the main reason this compound appears across so many different cancer models. ### What the Warburg effect means Cancer cells often rely on aerobic glycolysis. They convert glucose to lactate even when oxygen is available. That looks inefficient. It is actually useful for fast-growing tumours because it preserves carbon skeletons for nucleotide, amino-acid, and lipid synthesis. ### Why PKM2 matters Pyruvate kinase M2 helps control the final glycolytic step. In tumours, PKM2 is also more than a metabolic enzyme. Its dimeric form helps route glycolytic intermediates into biomass production and can support nuclear transcriptional programmes linked to survival. That is why tumour cells favour it. ### What shikonin does here Shikonin inhibits PKM2 and reduces glycolytic throughput. The main downstream effects include: * less lactate production * less ATP availability * less anabolic support for proliferation * weaker PKM2-linked transcriptional support in pathways such as STAT3 and ER-related signalling This has been shown in breast, bladder, oesophageal, hepatocellular, and pancreatic models. ### Why this is clinically relevant PKM2 is attractive because it is much more tumour-linked than many broad metabolic targets. That raises the hope of at least partial cancer-cell selectivity. It also means the mechanism can travel across cancer types instead of staying locked inside one subtype. ### The main limit PKM2 inhibition alone does not solve cancer. Tumours can shift metabolic routes. That is why shikonin is most interesting when PKM2 inhibition sits beside apoptosis, necroptosis, endocrine disruption, or combination therapy. ### Bottom line If one mechanism explains why shikonin keeps reappearing in oncology papers, this is it. PKM2 gives the compound a real unifying biology across cancer types. ### Key references Lv C et al. (2021). Shikonin inhibits ESCC tumour growth by suppressing PKM2-mediated aerobic glycolysis. *Journal of Cancer.*\ Shikonin differentially regulates glucose metabolism via PKM2 and the Warburg Effect. *Life Sciences* (2021).\ Li Z et al. (2018). PKM2 in resistant cancer cells — necroptosis link. *PMC.*\ Ahmad F et al. (2024). PKM2/metabolic findings across breast cancer subtypes. *Journal of Pharmacy and Pharmacology.*\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/pkm2-and-the-warburg-effect.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.